TYRA-300 has gained an investigational new drug application from the FDA and will be further studied in the phase 2 SURF302 trial for patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.
This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with…
Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.
No dose-limiting toxicities were observed with upamostat combination therapy in patients with metastatic pancreatic cancer.
After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and immune systems from the ground up from…
Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.
Join us for a virtual session where learners will hear from experts in the field in a didactic & panel case discussion format.
Communicating with friends and family during cancer treatment can be helpful but may also feel overwhelming. Social Work Counselor Niyati Purohit shares eight tips for…
To improve the quality of medical care in developing countries, ASH has partnered with Health Volunteers Overseas (HVO), a nonprofit organization dedicated to improving global…
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, patients with cancer-related cachexia who…
The fellowship provides a two-year grant of $130,000 to support the salary and benefits of the fellow while working on a mentored brain cancer research…
